S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
pixel
NASDAQ:RZLT

Rezolute Stock Forecast, Price & News

$6.50
0.00 (0.00 %)
(As of 10/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.36
$6.60
50-Day Range
$6.53
$11.35
52-Week Range
$5.86
$21.11
Volume72,358 shs
Average Volume43,676 shs
Market Capitalization$56.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.69
30 days | 90 days | 365 days | Advanced Chart
Receive RZLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.


Rezolute logo

About Rezolute

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RZLT
Employees
23
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.26 per share

Profitability

Net Income
$-20.33 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$56.03 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.49 out of 5 stars

Medical Sector

118th out of 1,359 stocks

Pharmaceutical Preparations Industry

50th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Rezolute (NASDAQ:RZLT) Frequently Asked Questions

Is Rezolute a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rezolute stock.
View analyst ratings for Rezolute
or view top-rated stocks.

What stocks does MarketBeat like better than Rezolute?

Wall Street analysts have given Rezolute a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rezolute wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Rezolute?

Rezolute saw a increase in short interest in September. As of September 30th, there was short interest totaling 7,100 shares, an increase of 343.8% from the September 15th total of 1,600 shares. Based on an average trading volume of 14,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.2% of the shares of the stock are sold short.
View Rezolute's Short Interest
.

When is Rezolute's next earnings date?

Rezolute is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Rezolute
.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) posted its quarterly earnings data on Tuesday, September, 14th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.03.
View Rezolute's earnings history
.

How has Rezolute's stock price been impacted by COVID-19 (Coronavirus)?

Rezolute's stock was trading at $0.0820 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RZLT shares have increased by 7,826.8% and is now trading at $6.50.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RZLT?

5 brokerages have issued 12-month price objectives for Rezolute's shares. Their forecasts range from $21.00 to $30.00. On average, they expect Rezolute's share price to reach $25.40 in the next twelve months. This suggests a possible upside of 290.8% from the stock's current price.
View analysts' price targets for Rezolute
or view top-rated stocks among Wall Street analysts.

Who are Rezolute's key executives?

Rezolute's management team includes the following people:
  • Nevan Charles Elam, President, Chief Executive Officer, CFO & Director
  • Michael Deperro, Vice President-Operations
  • Sankaram Mantripragada, Scientist Emeritus
  • Erin O’Boyle, Vice President-Clinical Operations
  • Davelyn Eaves Hood, Director-Scientific & Patient Affairs

What other stocks do shareholders of Rezolute own?

What is Rezolute's stock symbol?

Rezolute trades on the NASDAQ under the ticker symbol "RZLT."

How do I buy shares of Rezolute?

Shares of RZLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rezolute's stock price today?

One share of RZLT stock can currently be purchased for approximately $6.50.

How much money does Rezolute make?

Rezolute has a market capitalization of $56.03 million. The company earns $-20.33 million in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Rezolute have?

Rezolute employs 23 workers across the globe.

What is Rezolute's official website?

The official website for Rezolute is www.rezolutebio.com.

Where are Rezolute's headquarters?

How can I contact Rezolute?

Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 206-4507 or via email at [email protected].


This page was last updated on 10/23/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.